SubHero Banner

Vectibix® (panitumumab) – Expanded indication

June 29, 2017 – Amgen announced the FDA approval of Vectibix (panitumumab) for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as first line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine-, Eloxatin® (oxaliplatin)-, and irinotecan-containing chemotherapy.

Download PDF